Structure of Alisertib
CAS No.: 1028486-01-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50 = 1.2 nM) that binds to Aurora A kinase, causing mitotic spindle abnormalities and mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy by targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells, demonstrating antitumor activity.
Synonyms: MLN 8237
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1028486-01-2 |
Formula : | C27H20ClFN4O4 |
M.W : | 518.92 |
SMILES Code : | O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(OC)C=CC=C5F)=NC3)=N2)C=C1OC |
Synonyms : |
MLN 8237
|
MDL No. : | MFCD16621243 |
InChI Key : | ZLHFILGSQDJULK-UHFFFAOYSA-N |
Pubchem ID : | 24771867 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
GB169 neurosphere cells | 200 nM | 12 days | Induced apoptosis and senescence, reduced tumor cell proliferation | PMC4528677 |
GB30 neurosphere cells | 200 nM | 12 days | Induced apoptosis and senescence, reduced tumor cell proliferation | PMC4528677 |
GB9 neurosphere cells | 200 nM | 12 days | Induced apoptosis and senescence, reduced tumor cell proliferation | PMC4528677 |
ROSAKIT D816V cells | 500 nM | 24 h | To evaluate the induction of apoptosis by Alisertib in ROSAKIT D816V cells, results showed that Alisertib significantly induced apoptosis at submicromolar doses. | PMC9999558 |
HMC-1 cells | 500 nM | 24 h | To evaluate the induction of apoptosis by Alisertib in HMC-1 cells, results showed that Alisertib significantly induced apoptosis at submicromolar doses. | PMC9999558 |
CAMA-1 | 200 nM | 72 h | To investigate the cytotoxic effect of Alisertib on RB-deficient cells, results showed that RB-deficient cells were more sensitive to Alisertib, leading to apoptosis. | PMC10680093 |
T47D | 200 nM | 72 h | To investigate the cytotoxic effect of Alisertib on RB-deficient cells, results showed that RB-deficient cells were more sensitive to Alisertib, leading to apoptosis. | PMC10680093 |
MCF7 | 200 nM | 72 h | To investigate the cytotoxic effect of Alisertib on RB-deficient cells, results showed that RB-deficient cells were more sensitive to Alisertib, leading to apoptosis. | PMC10680093 |
A549 lung cancer cells | 500 nM | 7 days | Induced cellular senescence, enhanced SA-β-gal activity, and inhibited clonogenic capacity | PMC9460569 |
Hs294T cells | 1 μM | 3 days | Investigated the effect of Alisertib on DNA damage, finding that Alisertib increased the expression of the DNA damage marker γH2AX. | PMC5652019 |
SK-Mel5 cells | 1 μM | 3 days | Investigated the effect of Alisertib on DNA damage, finding that Alisertib increased the expression of the DNA damage marker γH2AX. | PMC5652019 |
DLD-1 | 0.05 µM, 0.1 µM, 0.2 µM | 72 h | To evaluate the anti-proliferative effects of Alisertib and TAK-733 alone and in combination, it was found that the combination showed stronger synergistic effects in KRAS/PIK3CA double-mutant cell lines. | PMC4468631 |
HCT116 | 0.05 µM, 0.1 µM, 0.2 µM | 72 h | To evaluate the anti-proliferative effects of Alisertib and TAK-733 alone and in combination, it was found that the combination showed stronger synergistic effects in KRAS/PIK3CA double-mutant cell lines. | PMC4468631 |
BCL cell lines (LY10, SU-DHL6, LY7, Jeko-1) | 10 to 1000 nM | 72 h | To evaluate the cytotoxic effect of Alisertib in BCL cell lines, results showed concentration-dependent cytotoxicity in BCL cell lines. | PMC4581881 |
TCL cell lines (C5MJ, DND41, H9, HH) | 10 to 1000 nM | 72 h | To evaluate the cytotoxic effect of Alisertib in TCL cell lines, results showed concentration-dependent cytotoxicity in TCL cell lines. | PMC4581881 |
MDA-MB-231 cells | 100 nM | 2 h | To investigate the effect of Alisertib on the ATP/ADP ratio in mitotic cells, results showed that Alisertib treatment significantly reduced the ATP/ADP ratio. | PMC8484571 |
MDA-MB-231 cells | 100 nM | 6 h | To investigate the effect of Alisertib on oxidative phosphorylation (OXPHOS) in cells, results showed that Alisertib treatment significantly reduced intracellular ATP levels. | PMC8484571 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Mice | MCF7 xenograft model | Oral | 10 mg/kg | 6 days a week for 3 weeks | To evaluate the therapeutic effect of Alisertib on RB-deficient tumors in vivo, results showed that Alisertib significantly inhibited the growth of RB-deficient tumors. | PMC10680093 |
Nude mice | Intracranial GB neurosphere xenograft model | Oral | 20 mg/kg | Twice daily, 5 days/week for 2 weeks | Extended median survival of mice, reduced tumor cell proliferation | PMC4528677 |
Mice | MYC-driven SCLC mouse model | Oral gavage | 20 mg/kg | 5 days on, 2 days off weekly, continuous treatment | To evaluate the effect of Alisertib in combination with CHK1 inhibitor Prexasertib on the survival of MYC-driven SCLC mouse model, results showed that the combination therapy significantly prolonged the survival of mice. | PMC6677768 |
Nude mice | Hs294T xenograft model | Subcutaneous injection | 30 mg/kg | Once daily for 3 weeks | Investigated the effect of Alisertib on tumor growth, finding that Alisertib significantly inhibited tumor growth. | PMC5652019 |
Nude mice | Colorectal cancer cell line xenograft models | Oral | 3 mg/kg | Once daily for 22 days | To evaluate the anti-tumor activity of Alisertib and TAK-733 alone and in combination in colorectal cancer cell line xenograft models, it was found that the combination showed synergistic effects in the HCT116 xenograft model. | PMC4468631 |
SCID mice | TCL xenograft model | Alisertib oral, Romidepsin intraperitoneal | 20 mg/kg | Alisertib daily for 21 days; Romidepsin on days 1, 9, 16 | To evaluate the synergistic effect of Alisertib and Romidepsin combination therapy in a TCL xenograft model, results showed significant tumor growth inhibition and improved survival. | PMC4581881 |
BALB/c mice | 4T1 xenograft model | Oral | 15 mg/kg | Once daily for 17 days | To investigate the tumor suppressive effect of Alisertib in combination with metformin, results showed that the combination treatment significantly inhibited tumor growth. | PMC8484571 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02551055 | Neoplasms, Advanced or Metasta... More >>tic Less << | Phase 1 | Terminated(Business Decision; ... More >>No Safety Or Efficacy Concerns.) Less << | - | United States, New York ... More >> Lake Success, New York, United States New York, New York, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, Texas Dallas, Texas, United States Houston, Texas, United States Spain Barcelona, Spain Less << |
NCT01540682 | Head and Neck Cancer | Phase 1 | Completed | - | United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less << |
NCT01316692 | Recurrent Melanoma ... More >> Stage IIIc Melanoma Stage IV Melanoma Less << | Phase 2 | Terminated(low accrual) | - | United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 Less << |
NCT01316692 | - | Terminated(low accrual) | - | - | |
NCT01677559 | Adenocarcinoma ... More >> Pancreatic Neoplasms Less << | Phase 1 | Completed | - | United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less << |
NCT02327169 | Advanced Nonhematologic Malign... More >>ancies Less << | Phase 1 | Completed | - | United States, Massachusetts ... More >> Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 2114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 2115 Dana Farber Cancer Institute Boston, Massachusetts, United States, 2115 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Texas The University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 France Institut Bergonie Bordeaux cedex, Gironde, France, 33076 Institut Claudius Regaud-Oncopole Toulouse cedex 09, Haute Garonne, France, 31059 Institut Gustave Roussy Villejuif cedex, Val De Marne, France, 94805 Spain Hospital Universitari Vall d'Hebron Barcelona, Spain, 8035 START Madrid. Fundacion Jimenez Diaz Madrid, Spain, 28040 Hospital Clinico Universitario Virgen de la Victoria Malaga, Spain, 29010 United Kingdom Sarah Cannon Research Institure UK London, Greater London, United Kingdom, W1G 6AD The Chrisie Manchester, Greater Manchester, United Kingdom, M20 4BX Churchill Hospital Oxford, Oxfordshire, United Kingdom, OX3 7LJ Less << |
NCT02780011 | CD30-positive Lymphoma ... More >> CD30-positive Solid Tumor Less << | Phase 1 | Withdrawn(lack of funding) | September 2018 | United States, Texas ... More >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01397825 | Diffuse Large B-Cell Lymphoma ... More >> Transformed Follicular Lymphoma Mantle Cell Lymphoma Burkitt's Lymphoma Less << | Phase 1 Phase 2 | Completed | - | - |
NCT01601535 | Neuroblastoma | Phase 1 Phase 2 | Active, not recruiting | December 2018 | United States, California ... More >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027-0700 Lucile Packard Children's Hospital at Stanford University Medical Center Palo Alto, California, United States, 94304 UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 United States, Colorado Children Hospital of Colorado Aurora, Colorado, United States, 80045 United States, Georgia Children's Healthcare of Atlanta Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Childrens Hospital Boston, Dana-Farber Cancer Institute. Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 United States, Texas Cook Children's Medical Center - Fort Worth Fort Worth, Texas, United States, 76104 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Less << |
NCT01034553 | - | Completed | - | - | |
NCT01397825 | - | Completed | - | - | |
NCT00500903 | Advanced Malignancies | PHASE1 | COMPLETED | 2011-02-23 | Sarah Cannon Research Institut... More >>e (SCRI), Nashville, Tennessee, 37203, United States Less << |
NCT00962091 | Advanced Solid Tumors | PHASE1 | COMPLETED | 2014-07-01 | Premiere Oncology, A Medical C... More >>orporation, Santa Monica, California, 90404, United States Less << |
NCT01034553 | Refractory Multiple Myeloma | Phase 1 Phase 2 | Completed | - | United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, California University of California, San Francisco San Fransisco, California, United States, 94143 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Less << |
NCT01154816 | Hepatoblastoma ... More >> Previously Treated Childhood Rhabdomyosarcoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Kidney Neoplasm Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent Osteosarcoma Less << | Phase 2 | Completed | - | - |
NCT01094288 | Advanced Solid Tumors ... More >> Adenocarcinoma of the Prostate Less << | Phase 1 | Completed | - | United States, Indiana ... More >> Indianapolis, Indiana, United States United States, Oregon Portland, Oregon, United States United States, Texas San Antonio, Texas, United States United States, Washington Seattle, Washington, United States Less << |
NCT01482962 | Relapsed Peripheral T-Cell Lym... More >>phoma Refractory Peripheral T-Cell Lymphoma Less << | Phase 3 | Completed | - | - |
NCT01154816 | - | Completed | - | - | |
NCT00651664 | Advanced Malignancies | Phase 1 | Completed | - | Spain ... More >> Ciutat Sanitaria Vall d'Hebron - Servicio de Oncologia Barcelona, Spain, 08035 H. Clínico Universitario de Valencia Valencia, Spain Less << |
NCT02560025 | Acute Myeloid Leukemia | Phase 2 | Active, not recruiting | October 2019 | United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less << |
NCT02114229 | Malignant Rhabdoid Tumor ... More >> Atypical Teratoid Rhabdoid Tumor Less << | Phase 2 | Recruiting | May 2027 | United States, California ... More >> Children's Hospital of Los Angeles Withdrawn Los Angeles, California, United States, 90027 Lucille Packard Children's Hospital at Stanford University Medical Center Recruiting Palo Alto, California, United States, 94304 Contact: Sonia Partap, MD 650-723-0993 spartap@stanford.edu Principal Investigator: Sonia Partap, MD Rady Children's Hospital Recruiting San Diego, California, United States, 92123 Contact: John Crawford, MD, MS 858-576-1700 jcrawford@rchsd.org Principal Investigator: John Crawford, MD, MS United States, Colorado Children's Hospital Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Kathleen Dorris, MD 720-777-6672 kathleen.dorris@childrenscolorado.org Principal Investigator: Kathleen Dorris, MD United States, District of Columbia Children's National Medical Center Recruiting Washington, District of Columbia, United States, 20010 Contact: Lindsay B. Kilburn, MD 202-476-2800 lkilburn@childrensnational.org Principal Investigator: Lindsay B. Kilburn, MD United States, Florida UF Cancer Center at Orlando Health Recruiting Orlando, Florida, United States, 32806 Contact: Amy A. Smith, MD 321-841-7246 amy.smith@orlandohealth.com Principal Investigator: Amy A. Smith, MD United States, Georgia Children's Healthcare of Atlanta Recruiting Atlanta, Georgia, United States, 30322 Contact: Sindy Moon 404-785-1441 cindy.moon@choa.org Contact: Jaclyn Smith 404-785-0692 jaclyn.smith@choa.org Principal Investigator: Dolly Aguilera, MD United States, Minnesota Children's Hospital and Clinics of Minnesota Recruiting Minneapolis, Minnesota, United States, 55102 Contact: Anne Bendel, MD 651-220-6732 anne.bendel@childrensmn.org Principal Investigator: Anne Bendel, MD United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Tabatha E. Doyle, RN 901-595-2544 tabatha.doyle@stjude.org Principal Investigator: Santhosh Upadhyaya, MD United States, Texas Texas Children's Hospital Recruiting Houston, Texas, United States, 77030 Contact: Patricia Baxter, MD 832-824-1000 pabaxter@txch.org Principal Investigator: Patricia Baxter, MD United States, Washington Seattle Children's Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Sarah Leary, MD 866-987-2000 sarah.leary@seattlechildrens.org Principal Investigator: Sarah Leary, MD Less << |
NCT01897012 | MYC Positive ... More >>Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent Hodgkin Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Less << | Phase 1 | Active, not recruiting | - | United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT03005262 | - | - | - | - | |
NCT02560025 | - | Active, not recruiting | - | - | |
NCT02038647 | Small Cell Lung Cancer (SCLC) | Phase 2 | Active, not recruiting | August 7, 2017 | - |
NCT01471964 | Non-small Cell Lung Cancer Met... More >>astatic Non-small Cell Lung Cancer Recurrent Less << | Phase 1 Phase 2 | Terminated(Phase I portion com... More >>pleted. Phase II will open pending amendment approval.) Less << | - | United States, Pennsylvania ... More >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less << |
NCT01482962 | - | Completed | - | - | |
NCT01695941 | Recurrent B-Cell Non-Hodgkin L... More >>ymphoma Recurrent Mantle Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Mantle Cell Lymphoma Less << | Phase 1 | Active, not recruiting | - | United States, New York ... More >> Montefiore Medical Center-Einstein Campus Bronx, New York, United States, 10461 Montefiore Medical Center - Moses Campus Bronx, New York, United States, 10467 Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York, United States, 10016 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less << |
NCT02367352 | Advanced Solid Tumors ... More >> Ovarian Cancer Small Cell Lung Cancer Less << | Phase 1 | Completed | - | Japan ... More >> Chiba, Japan Shizuoka, Japan Korea, Republic of Seoul, Korea, Republic of Less << |
NCT01923337 | Mucinous Adenocarcinoma of the... More >> Colon Mucinous Adenocarcinoma of the Rectum Recurrent Colon Cancer Recurrent Rectal Cancer Signet Ring Adenocarcinoma of the Colon Signet Ring Adenocarcinoma of the Rectum Stage IIIA Colon Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Active, not recruiting | December 2019 | United States, California ... More >> UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 Less << |
NCT02444884 | Unspecified Childhood Solid Tu... More >>mor, Excluding CNS Neuroblastoma Less << | Phase 1 | Completed | - | - |
NCT01924260 | Acinar Cell Adenocarcinoma of ... More >>the Pancreas Duct Cell Adenocarcinoma of the Pancreas Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << | Phase 1 | Active, not recruiting | December 2020 | United States, California ... More >> UC Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 Less << |
NCT01466881 | Adult Nasal Type Extranodal NK... More >>/T-Cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Hepatosplenic T-Cell Lymphoma Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Recurrent Adult Non-Hodgkin Lymphoma Recurrent Adult T-Cell Leukemia/Lymphoma Less << | Phase 2 | Completed | - | - |
NCT01045421 | - | Completed | - | - | |
NCT01637961 | Recurrent Uterine Corpus Sarco... More >>ma Uterine Corpus Leiomyosarcoma Less << | Phase 2 | Completed | - | - |
NCT01637961 | - | Completed | - | - | |
NCT01466881 | - | Completed | - | - | |
NCT01799278 | Small Cell Prostate Cancer ... More >> Neuroendocrine Prostate Cancer Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers Less << | Phase 2 | Completed | - | United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Weill Cornell Medical College New York, New York, United States, 10065 United States, North Carolina Duke University Health System Durham, North Carolina, United States, 27710 United States, Ohio University Hospitals Cleveland Medical Center Cleveland, Ohio, United States, 44106 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98195 Less << |
NCT01653028 | - | Completed | - | - | |
NCT00697346 | B-cell Follicular Lymphoma|B-c... More >>ell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma|B-Cell Chronic Lymphocytic Leukemia|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma|NK Lymphoma Less << | PHASE1 | COMPLETED | 2016-10-19 | Scottsdale, Arizona, United St... More >>ates|Lexington, Kentucky, United States|Baltimore, Maryland, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|Buffalo, New York, United States|Chapel Hill, North Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States Less << |
NCT01091428 | Ovarian Carcinoma ... More >> Fallopian Tube Cancer Peritoneal Cancer Breast Carcinoma Less << | Phase 2 | Completed | - | United States, New York ... More >> Bronx, New York, United States United States, Pennsylvania Philadelphia, Pennsylvania, United States United States, Texas Houston, Texas, United States United States, Washington Seattle, Washington, United States Less << |
NCT02319018 | Malignant Digestive System Neo... More >>plasm Less << | Phase 1 | Completed | - | United States, Connecticut ... More >> Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States, 06510 Yale University New Haven, Connecticut, United States, 06520 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Michigan Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less << |
NCT01045421 | Advanced Nonhematological Mali... More >>gnancies Non-Small Cell Lung Cancer Small Cell Lung Cancer Metastatic Breast Cancer Head and Neck Squamous Cell Carcinoma Gastroesophageal Adenocarcinoma Less << | Phase 1 Phase 2 | Completed | - | United States, Texas ... More >> Houston, Texas, United States United States, Utah Salt Lake City, Utah, United States Less << |
NCT01639911 | Malignant Neoplasm of Breast ... More >> CNS Malignancy Malignant Neoplasm of Gastrointestinal Tract Genitourinary Neoplasms Malignancy and Gender Unspecified Head and Neck Neoplasms Melanoma Malignant Neoplasm of Thorax Less << | Phase 1 | Completed | - | United States, Illinois ... More >> University of Illinois Cancer Center Chicago, Illinois, United States, 60612 Less << |
NCT01653028 | Myxofibrosarcoma ... More >> Recurrent Adult Soft Tissue Sarcoma Recurrent Leiomyosarcoma Recurrent Liposarcoma Recurrent Malignant Peripheral Nerve Sheath Tumor Recurrent Undifferentiated Pleomorphic Sarcoma Stage III Soft Tissue Sarcoma AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Less << | Phase 2 | Completed | - | - |
NCT00853307 | Ovarian Carcinoma | PHASE2 | COMPLETED | 2011-01-27 | Summit Medical Group, Berkeley... More >> Heights, New Jersey, 07922, United States Less << |
NCT00853307 | Ovarian Carcinoma | PHASE2 | COMPLETED | 2011-01-27 | Summit Medical Group, Berkeley... More >> Heights, New Jersey, 07922, United States Less << |
NCT01567709 | Adult B Acute Lymphoblastic Le... More >>ukemia Adult T Acute Lymphoblastic Leukemia Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Chronic Lymphocytic Leukemia Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Hepatosplenic T-Cell Lymphoma Intraocular Lymphoma Lymphomatous Involvement of Non-Cutaneous Extranodal Site Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Nodal Marginal Zone Lymphoma Primary Cutaneous B-Cell Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides and Sezary Syndrome Recurrent Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Small Intestinal Lymphoma Splenic Marginal Zone Lymphoma T-Cell Large Granular Lymphocyte Leukemia Testicular Lymphoma Waldenstrom Macroglobulinemia Less << | Phase 1 | Completed | - | United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Less << |
NCT01091428 | - | Completed | - | - | |
NCT01799278 | - | Completed | - | - | |
NCT00830518 | Acute Myelogenous Leukemia|Hig... More >>h-Grade Myelodysplastic Syndrome Less << | PHASE2 | COMPLETED | 2011-07-04 | Hematology and Oncology Associ... More >>ates of Northern New Jersey, Morristown, New Jersey, 07962, United States Less << |
NCT02187991 | Breast Cancer ... More >> Breast Carcinoma Breast Tumors Malignant Neoplasm of Breast Less << | Phase 2 | Active, not recruiting | September 2019 | United States, Texas ... More >> 22 Sites Including Dallas And Austin, Texas, United States Less << |
NCT01848067 | Adenocarcinoma of the Prostate... More >> Hormone-resistant Prostate Cancer Recurrent Prostate Cancer Stage IV Prostate Cancer Less << | Phase 1 Phase 2 | Completed | - | United States, Pennsylvania ... More >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less << |
NCT01848067 | - | Completed | - | - | |
NCT01779843 | Acute Myelogenous Leukemia | Phase 1 | Completed | - | United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less << |
NCT00830518 | Acute Myelogenous Leukemia|Hig... More >>h-Grade Myelodysplastic Syndrome Less << | PHASE2 | COMPLETED | 2011-07-04 | Hematology and Oncology Associ... More >>ates of Northern New Jersey, Morristown, New Jersey, 07962, United States Less << |
NCT02219789 | Estrogen Receptor Positive ... More >> Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << | Phase 1 | Completed | - | United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT01812005 | - | Terminated(Slow patient enroll... More >>ment and study discontinued after 14 patients enrolled) Less << | - | - | |
NCT01812005 | Extranodal Marginal Zone B-cel... More >>l Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Splenic Marginal Zone Lymphoma Waldenstr?m Macroglobulinemia Less << | Phase 2 | Terminated(Slow patient enroll... More >>ment and study discontinued after 14 patients enrolled) Less << | - | United States, Georgia ... More >> Emory University Atlanta, Georgia, United States, 30322 United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less << |
NCT02860000 | Estrogen Receptor Status ... More >> HER2/Neu Negative Invasive Breast Carcinoma Postmenopausal Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Less << | Phase 2 | Recruiting | December 15, 2021 | United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Clinical Trials Referral Office 855-776-0015 Principal Investigator: Tufia C. Haddad Less << |
NCT00807495 | Diffuse Large B-cell Lymphoma|... More >>Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component Less << | PHASE2 | COMPLETED | 2013-02-13 | Hematology Oncology Associates... More >>, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, 08060, United States Less << |
NCT00807495 | Diffuse Large B-cell Lymphoma|... More >>Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component Less << | PHASE2 | COMPLETED | 2013-02-13 | Hematology Oncology Associates... More >>, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, 08060, United States Less << |
NCT02259010 | Advanced Solid Tumors ... More >> Relapsed/Refractory Lymphoma Less << | Phase 1 | Unknown | April 2016 | United States, Missouri ... More >> St. Louis, Missouri, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, Tennessee Germantown, Tennessee, United States United States, Texas Dallas, Texas, United States Less << |
NCT01613261 | Advanced Nonhematologic Malign... More >>ancies Less << | Phase 1 | Withdrawn | November 2015 | United States, Texas ... More >> South Texas Accelerated Research Therapeutics (START) San Antonio, Texas, United States, 78229 Less << |
NCT02109328 | Bladder Cancer ... More >> Transitional Cell Carcinoma Less << | Phase 2 | Unknown | March 2018 | Italy ... More >> Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milano, Mi, Italy, 20133 Contact: Andrea Necchi, MD +39022390 ext 2402 andrea.necchi@istitutotumori.mi.it Sub-Investigator: Patrizia Giannatempo, MD Principal Investigator: Andrea Necchi, MD Less << |
NCT02530619 | Acute Megakaryoblastic Leukemi... More >>a Myelofibrosis Primary Myelofibrosis Less << | Not Applicable | Active, not recruiting | March 2020 | United States, Florida ... More >> University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States, 33136 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT01844583 | Solid Tumors ... More >>Lymphoma Less << | Phase 1 | Completed | - | United States, Florida ... More >> Sarasota, Florida, United States United States, Missouri St. Louis, Missouri, United States United States, Oklahoma Oklahoma City, Oklahoma, United States United States, Tennessee Nashville, Tennessee, United States United States, Texas Dallas, Texas, United States San Antonio, Texas, United States Less << |
NCT02293005 | Lung Cancer|Mesothelioma | PHASE2 | COMPLETED | 2021-07-06 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT01512758 | Advanced Solid Tumors|Lymphoma... More >>s Less << | PHASE1 | COMPLETED | 2013-10-08 | National Cancer Centre, Tiong ... More >>Bahru, 169610, Singapore Less << |
NCT02700022 | Diffuse Large B-cell Lymphoma|... More >>Follicular Lymphoma|Burkitt Lymphoma Less << | PHASE1 | TERMINATED | 2017-08-18 | City of Hope Comprehensive Can... More >>cer Center, Duarte, California, 91010, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, 27599, United States Less << |
NCT01898078 | Advanced Solid Tumors|Lymphoma | PHASE1 | COMPLETED | 2017-01-24 | Bronx, New York, United States... More >>|Nashville, Tennessee, United States|San Antonio, Texas, United States Less << |
NCT02186509 | Adult Anaplastic Astrocytoma ... More >> Adult Anaplastic Ependymoma Adult Anaplastic Oligodendroglioma Adult Brain Stem Glioma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Oligodendroglioma Adult Pilocytic Astrocytoma Adult Pineal Gland Astrocytoma Adult Subependymal Giant Cell Astrocytoma Recurrent Adult Brain Tumor Less << | Phase 1 | Active, not recruiting | January 2019 | United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less << |
NCT02719691 | Metastatic Breast Cancer ... More >> Solid Tumors Less << | Phase 1 | Recruiting | November 2018 | United States, Colorado ... More >> University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Matthew Lee 303-848-0630 matthew.lee@ucdenver.edu Principal Investigator: Jennifer Diamond, MD Less << |
NCT02214147 | Advanced Solid Tumors|Relapsed... More >>/Refractory Lymphoma Less << | PHASE1 | COMPLETED | 2016-07-18 | Miami, Florida, United States|... More >>Chicago, Illinois, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States Less << |
NCT02214147 | Advanced Solid Tumors|Relapsed... More >>/Refractory Lymphoma Less << | PHASE1 | COMPLETED | 2016-07-18 | Miami, Florida, United States|... More >>Chicago, Illinois, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States Less << |
NCT02812056 | Malignant Neoplasms of Digesti... More >>ve Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Lip Oral Cavity and Pharynx Malignant Neoplasms of Male Genital Organs Less << | Phase 1 | Withdrawn | - | - |
NCT01714947 | Advanced Solid Tumors ... More >> Lymphoma Less << | Phase 1 | Completed | - | United States, Washington ... More >> Comprehensive Clinical Development Tacoma, Washington, United States, 98418 Less << |
NCT01714947 | - | Completed | - | - | |
NCT06095505 | Small Cell Lung Cancer | PHASE2 | RECRUITING | 2026-01-31 | Southern Cancer Center, Daphne... More >>, Alabama, 36526, United States|The Oncology Institute of Hope and Innovation, Long Beach, California, 90805, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, 80124, United States|Georgetown Lombardi Cancer Center, Washington, District of Columbia, 20057, United States|The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida, 33316, United States|Moffitt Cancer Center, Tampa, Florida, 33612, United States|Illinois Cancer Specialists, Niles, Illinois, 60714, United States|University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, 21201, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Henry Ford Hospital, Detroit, Michigan, 48202, United States|Minnesota Oncology Hematology, Burnsville, Minnesota, 55337, United States|Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, 45226, United States|University Hospital - Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Zangmeister Cancer Center, Columbus, Ohio, 43219, United States|Oncology Associates of Oregon, Eugene, Oregon, 97401, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, 15232, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, 29425, United States|SCRI Oncology Partners, Nashville, Tennessee, 37203, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Oncology & Hematology Associates of Southwest Virginia, Blacksburg, Virginia, 24073, United States|Universtity of Virginia Health System, Charlottesville, Virginia, 22908, United States|Virginia Cancer Specialists Research Institute, Fairfax, Virginia, 22031, United States|Northwest Cancer Specialists, Vancouver, Washington, 98686, United States|Marshfield Medical Center, Marshfield, Wisconsin, 54449, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.93mL 0.39mL 0.19mL |
9.64mL 1.93mL 0.96mL |
19.27mL 3.85mL 1.93mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|